
US advances first government-funded trials of psychedelic drug ibogaine
The United States Food and Drug Administration is advancing government-funded clinical trials investigating the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. Health officials opened a public docket seeking feedback on trial design, safety monitoring, patient eligibility, and dosage limits following an executive order. Ibogaine, derived from...








